Harel Insurance Investments & Financial Services Ltd. Reduces Stock Position in Medpace Holdings, Inc. $MEDP

Harel Insurance Investments & Financial Services Ltd. trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,071 shares of the company’s stock after selling 1,809 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Medpace were worth $6,757,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of MEDP. BOKF NA raised its stake in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after buying an additional 24 shares in the last quarter. Schulhoff & Co. Inc. grew its holdings in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC raised its position in shares of Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after buying an additional 26 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

MEDP has been the topic of several research analyst reports. Royal Bank Of Canada reduced their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. BMO Capital Markets reduced their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Robert W. Baird restated a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their price objective for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus target price of $469.50.

Medpace Stock Down 1.3%

Shares of Medpace stock opened at $529.23 on Thursday. The company has a 50 day moving average of $473.64 and a 200 day moving average of $494.66. The company has a market capitalization of $15.11 billion, a P/E ratio of 33.26, a P/E/G ratio of 2.72 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $306.70 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the firm earned $3.67 earnings per share. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.